Research Explorer

Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.

Project

A targeted nanomedicine strategy for in vivo CD8+ T cell engineering

Outputs and Outcomes

Code

01D03021

Duration

01 October 2021 → 31 October 2022

Funding

Regional and community funding: Special Research Fund

Promotor

Bruno De Geest

Fellow

Justine Aelvoet

Research disciplines

Medical and health sciences
- Applied immunology
- Biopharmaceuticals
- Pharmaceutical technology
Engineering and technology
- Nanomaterials

Keywords

immunotherapy T cells cancer nanotechnology

Project description

The goal of this project is to investigate a strategy to target CD8+ T cells in vivo for subsequent cellspecific
delivery of nanoparticle-formulated therapeutics. Via this technology, we aim to modulate T cells in vivo in the blood and in the tumor microenvironment.

English

Dutch

English

Cookie settings

In addition to functional cookies which are necessary for the website to function, Ghent University uses non-functional cookies such as statistical cookies and social media cookies. These non-functional cookies can also be placed by third parties, for example to measure the use of the site or to share content on social media. Certain media are only available if you accept the cookies. You can set and modify your cookie preferences yourself. Find out what cookies we use and why in the Cookie Statement.

Analytics

AnalyticsWe'll collect information about your visit to our site. It helps us understand how the site is used – what's working, what might be broken and what we should improve.

Powered by